Current Opinion in Chemical Biology
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
Publication date: October 2022Source: Current Opinion in Chemical Biology, Volume 70Author(s): Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Brar, Deepak B. Salunke, Nikolai Petrovsky